• About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

o2h-ventures

  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

Don’t invest unless you’re prepared to lose all your money invested. This is a high risk investment. You could lose all the money you invest and are unlikely to be protected if something goes wrong. Take 2 mins to learn more

o2h Ventures deals pipeline, Knowledge-intensive EIS Fund closing on 5th April 2023
Mar 1 2023

We are nearing the close of another round of successful investment in the o2h human health Funds. The table below shows investments that you could be investing into over the coming months. The final date to receive cleared funds is the 5th April 2023 for the Knowledge-intensive Human Health EIS fund.

Below is the selection of opportunities –

Metrion

Biotech – Services
Metrion is a specialist ion channel contract research organisation (CRO), based in Granta Park, Cambridge, UK. The Company provides a wide range of ion channel assay services to the worldwide pharmaceutical and bioscience industry. Ion channels are a major target for new drug discovery and also important in safety assessment. Metrion is a leader in its field and generated revenues of £5.3m in 2022, a 56% increase on 2021, while also reporting positive EBITDA. Metrion is seeking growth capital to expand its laboratory capacity, provide regulated (GLP) cardiac safety services and expand its business development capabilities in the USA. o2h Ventures has pre-emption rights to ensure deal access.

Alevin Therapeutics

Biotech – Lung
A Spin-out from the University of Nottingham now based in Cambridge, UK, was Seeded by o2h Ventures and Nottingham University. The company has a platform of over 500 compounds targeted against various integrins, with the most advanced molecules being progressed as a potential treatment for Idiopathic Pulmonary Fibrosis (IPF). This is a life-limiting condition, approximately 3 to 5 years from diagnosis, in which the lungs become scarred and breathing becomes increasingly difficult resulting in a very poor quality of life for patients. 1The Global Idiopathic Pulmonary Fibrosis Market is set to reach $10.1 Billion by 2029. Alevin recently won the prestigious industry award for Best Biotech Startup award for best start-up of the year from the OBN. o2h Ventures has pre-emption rights to ensure deal access.

Exonate

Biotech – Ocular
A spin-out from the University of Nottingham and now based in Cambridge, UK aims to introduce a revolutionary, game-changing eye drop for the treatment of retinal vascular diseases, including wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Oedema (DME), by using mRNA targeted therapies. The company has successfully completed its Phase I in Australia study and will now seek further investment to conduct a Phase II clinical trial in the USA. o2h Ventures has pre-emption rights to ensure deal access.

Somaserve

Biotech – Nanoparticle
A spinout of University College London (UCL) and now based at the Babraham Research Campus, Cambridge, UK is developing its patented targeted nanoparticle technology, PolyNaut® for use in a therapeutic setting to allow genetic materials to cross the blood brain barrier and other biological barriers. The business model is to exploit the polyNaut platform through the development of an internal pipeline focusing on rare, genetically driven diseases and early collaboration with pharmaceutical companies. Licences with significant upfronts, milestones, and royalties are expected from both platform and products. The company has several on-going collaborations with pharma and biotech, of which 5 are in the top 20 pharma. o2h Ventures has pre-emption rights to ensure deal access.

Turbine

Tech Bio
A company that utilises Machine Learning to predict experimental outcomes with their Simulated Cell™ platform. These simulations can decrease the timelines of drug discovery and development and boost the chances of clinical success. Turbine has 2 current collaborations with big pharma. Turbine recently raised Euro20M from Mercia and Mercks Venture fund and o2h Ventures will seek to use its pre-emption rights to join this investment round.

Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
  • youtube
o2h-ventures
related stories
  • o2h Ventures qualified as a finalist as Best EIS Manager – Specialist at Growth Investor Awards 2023 14 August, 2023
  • o2h Ventures selected as finalist for best seed VC in UKBAA awards 2023 14 June, 2023
  • o2h Ventures recognized as a finalist for the EISA Impact Award for 2023 8 June, 2023

Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.

Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.

o2h-ventures
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.
Useful Links
  • About Us
  • Blog
  • Documents Centre
  • Contact Us
  • Team
News
  • o2h Ventures qualified as a finalist as Best EIS Manager – Specialist at Growth Investor Awards 2023
  • o2h Ventures selected as finalist for best seed VC in UKBAA awards 2023
  • o2h Ventures recognized as a finalist for the EISA Impact Award for 2023
Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
© 2023 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us
This website is a financial promotion approved by o2h Ventures Ltd for the purposes of section 21 Financial Services and Markets Act 2000 relating to the communication of invitations or inducements to engage in investment activity. o2h ventures Limited is regulated and authorised by the Financial Conduct Authority. The FCA firm reference number is 812245 and further information can be found on the Financial Services Register.

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)